|Articles|October 2, 2015
- BioPharm International-10-15-2015
- Volume 2015 eBook
- Issue 2
Fluctuating Capacity and Demand Conditions in Biomanufacturing
Author(s)Randi Hernandez
BioPharm International eBooks
Advertisement
BioPharm International
eBooks Volume 28, Issue 14
Contract manufacturing is a booming business, especially considering that many pharmaceutical companies-including those with a focus on biologic products- are no longer conducting much of their own research and development in-house. Fewer still are capable of scaling up from laboratory to commercial production without some type of outside help from a contract manufacturing organization (CMO). Read this article and other articles in
BioPharm International
's 2015
eBook.
Articles in this issue
about 10 years ago
Cleaning Validation for Biologicsabout 10 years ago
Automation of Single-Use Systemsabout 10 years ago
Are Biopharma Patents Poised on the Post-Grant Chopping Block?about 10 years ago
Raising the Bar for Biopharma TrainingNewsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
Why Flexibility and Commercial Viability Must Be Built-in Early for Scaling CGTs
2
How Rentschler Biopharma’s New Platforms Aim to Accelerate Biologics Development in Asia
3
Analyzing the Safety and Scope of Next-Generation Gene Editing Platforms
4
